参考文献/References:
[1] Writing Committee Members;Otto CM,Nishimura RA,et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2021,77(4):450-500.
[2] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561-632.
[3] Matta A,Regueiro A,Urena M,et al. Comparison of paravalvular leak in SAPIEN 3 and EVOLUT PRO valves in transcatheter aortic valve replacement:a multicenter registry[J]. Am J Cardiol,2023,207:114-120.
[4] Welle GA,El-Sabawi B,Thaden JJ,et al. Effect of a fourth-generation transcatheter valve enhanced skirt on paravalvular leak[J]. Catheter Cardiovasc Interv,2021,97(5):895-902.
[5] Kini AS,Tang GHL,Yaryura R,et al. 1-Year real-world outcomes of TAVR?with the fifth-generation balloon-expandable valve in the united?states[J]. JACC Cardiovasc Interv,2025,18(6):785-797.
[6] 李玄庶,徐东辉,冯翔,等. 经导管主动脉瓣置换术应用于二、三叶式主动脉瓣狭窄的疗效比较[J]. 心脏杂志,2023,35(5):570-573.
[7] Makkar RR,Yoon SH,Chakravarty T,et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke among patients at low surgical risk[J]. JAMA,2021,326(11):1034-1044.
[8] Almeida JG,Ferreira SM,Fonseca P,et al. Comparison of self-expanding and balloon-expandable transcatheter aortic valves morphology and association with paravalvular regurgitation:evaluation using multidetector computed tomography[J]. Catheter Cardiovasc Interv,2018,92(3):533-541.
[9] Montalto C,Sticchi A,Crimi G,et al. Outcomes after transcatheter aortic valve replacement in bicuspid versus tricuspid anatomy:a systematic review and meta-analysis[J]. JACC Cardiovasc Interv,2021,14(19):2144-2155.
[10] Zito A,Buono A,Scotti A,et al. Incidence,predictors,and outcomes of paravalvular regurgitation after TAVR in Sievers type 1 bicuspid aortic valves[J]. JACC Cardiovasc Interv,2024,17(14):1652-1663.
[11] Fujita B,Kütting M,Seiffert M,et al. Calcium distribution patterns of the aortic valve as a risk factor for the need of permanent pacemaker implantation after transcatheter aortic valve implantation[J]. Eur Heart J Cardiovasc Imaging,2016,17(12):1385-1393.
[12] 王蔚然,孙泽瑜,辛然,等. 主动脉瓣复合体钙化分布密度是国产自膨式瓣膜TAVR术后传导障碍的危险因素[J]. 南方医科大学学报,2023,43(11):1901-1908.
[13] Auffret V,Puri R,Urena M,et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives[J]. Circulation,2017,136(11):1049-1069.
[14] Levack MM,Kapadia SR,Soltesz EG,et al. Prevalence of and risk factors for permanent pacemaker implantation after aortic valve replacement[J]. Ann Thorac Surg,2019,108(3):700-707.
[15] van Rosendael PJ,Delgado V,Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices:a systematic review[J]. Eur Heart J,2018,39(21):2003- 2013.
[16] Regueiro A,Abdul-Jawad Altisent O,Del Trigo M,et al. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis[J]. Circ Cardiovasc Interv,2016,9(5):e003635.
[17] Ueshima D,Nai Fovino L,Mojoli M,et al. The interplay between permanent pacemaker implantation and mortality in patients treated by transcatheter aortic valve implantation:a systematic review and meta-analysis[J]. Catheter Cardiovasc Interv,2018,92(3):E159- E167.
[18] Chamandi C,Barbanti M,Munoz-Garcia A,et al. Long-term outcomes in patients with new-onset persistent left bundle branch block following TAVR[J]. JACC Cardiovasc Interv,2019,12(12):1175-1184.
[19] Mohananey D,Jobanputra Y,Kumar A,et al. Clinical and echocardiographic outcomes following permanent pacemaker implantation after transcatheter aortic valve replacement:meta-analysis and meta-regression[J]. Circ Cardiovasc Interv 2017,10(7):e005046.
[20] Glikson M,Nielsen JC,Kronborg MB,et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology(ESC) With the special contribution of the European Heart Rhythm Association(EHRA)[J]. Rev Esp Cardiol(Engl Ed),2022,75(5):430.
[21] Thyregod HGH,J?rgensen TH,Ihlemann N,et al. Transcatheter or surgical aortic valve implantation:10-year outcomes of the NOTION trial[J]. Eur Heart J,2024,45(13):1116-1124.
[22] 中国医师协会心血管内科医师分会结构性心脏病学组,亚太结构性心脏病俱乐部. 中国经导管主动脉瓣置换术临床路径专家共识（2024版）[J]. 中国胸心血管外科临床杂志,2024,31(12):1713-1727.
[23] Yerasi C,Rogers T,Forrestal BJ,et al. Transcatheter versus surgical aortic valve replacement in young,low-risk patients with severe aortic stenosis[J]. JACC Cardiovasc Interv,2021,14(11):1169-1180.
[24] Fukuhara S,Wu X, D eeb GM. Surgical explant of transcatheter aortic bioprosthesis: results and clinical implications from the Society of Thoracic Surgeons Adult Cardiac Database Analysis[J]. J Am Coll Cardiol,2020,75(11) :2113.
[25] Fukuhara S,Nguyen CTN,Yang B,et al. Surgical explantation of transcatheter aortic bioprostheses:balloon vs self-expandable devices[J]. Ann Thorac Surg,2022,113(1):138-145.
[26] Ojeda S,González-Manzanares R,Jiménez-Quevedo P,et al. Coronary obstruction after transcatheter aortic valve replacement:insights from the Spanish TAVI Registry[J]. JACC Cardiovasc Interv,2023,16(10):1208-1217.
[27] Ribeiro HB,Rodés-Cabau J,Blanke P,et al. Incidence,predictors,and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves:insights from the VIVID registry[J]. Eur Heart J,2018,39(8):687-695.
[28] Barbanti M,Webb JG,Tamburino C,et al. Outcomes of redo transcatheter aortic valve replacement for the treatment of postprocedural and late occurrence of paravalvular regurgitation and transcatheter valve failure[J]. Circ Cardiovasc Interv,2016,9(9):e003930.
[29] Landes U,Webb J G,de Backer O,et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction[J]. J Am Coll Cardiol,2020,75(16):1882-1893.
[30] Bhogal S,Waksman R,Shea C,et al. Self-expanding and balloon-expandable valves in low risk TAVR patients[J]. Int J Cardiol,2024,395:131431.
[31] Dvir D,Leon MB,Abdel-Wahab M,et al. First-in-human dedicated leaflet splitting device for prevention of coronary obstruction in transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2023,16(1):94-102.
[32] Petersen JK, ?stergaard L,Carlson N,et al. Impact of acute kidney injury after transcatheter aortic valve replacement:a?nationwide study[J]. J Am Heart Assoc,2024,13(1):e031019.
[33] Najjar M,Salna M,George I. Acute kidney injury after aortic valve replacement:incidence,risk factors and outcomes[J]. Expert Rev Cardiovasc Ther,2015,13(3):301-316.
[34] Alhamad FS,Almohaimeed YS,Alhayzan MH,et al. Prevalence and risk factors associated with acute kidney injury after transcatheter aortic valve replacement at a tertiary hospital in Riyadh,Saudi Arabia[J]. Cureus,2023,15(8):e43381.
[35] Ktenopoulos N,Apostolos A,Chlorogiannis DD,et al. Association of urgent transcatheter aortic valve replacement(TAVR) with acute kidney injury 30-days post-TAVR:a systematic review and meta-analysis[J]. Eur Heart J Acute Cardiovasc Care,2024,13(suppl 1)：i300.
[36] Abdul-Jawad Altisent O,Durand E,Mu?oz-García AJ,et al. Warfarin and antiplatelet therapy versus?warfarin alone for treating patients?with?atrial fibrillation undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2016,9(16):1706-1717.
[37] Dangas GD,Tijssen JGP,W?hrle J,et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement[J]. N Engl J Med,2020,382(2):120-129.
[38] Al Said S,Kaier K,Nury E,et al. Non-vitamin K a ntagonist oral anticoagulants(NOACs) after transcatheter aortic valve replacement(TAVR):a network meta-analysis[J]. Cochrane Database Syst Rev,2025,2(2):Cd013745.
[39] Wang L,Sang W,Jian Y,et al. Post-TAVR patients with atrial fibrillation:are NOACs better than VKAs?—A meta-analysis[J]. Front Cardiovasc Med,2023,10:1175215.
[40] An Q,Su S,T u Y,et al. Efficacy and safety of antithrombotic therapy with non-vitamin K antagonist oral anticoagulants after transcatheter aortic valve replacement:a systematic review and meta-analysis[J]. Ther Adv Chronic Dis,2021,12:20406223211056730.
[41] Shashank S,Balireddi LD,Inban P,et al. Subclinical leaflet thrombosis and anticoagulation strategy following trans-catheter aortic valve replacement:a systematic review[J]. Health Sci Rep,2024,7(6):e2200.
[42] Rashid HN,Rajani R,Leipsic J,et al. Computed tomography imaging for subclinical leaflet thrombosis following surgical and transcatheter aortic valve replacement[J]. J Cardiovasc Comput Tomogr,2023,17(1):2-10.
[43] Bansal A,Agarwal S,Braghieri L,et al. Subclinical leaflet thrombosis after balloon versus self-expandable transcatheter aortic valve implantation[J]. Am J Cardiol,2023,192:88-97.
相似文献/References:
[1]于海波,综述,梁延春,等.经导管主动脉瓣膜置换术后房室传导阻滞的预警[J].心血管病学进展,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
YU Haibo,LIANG Yanchun.Predicting Factors of Atrioventricular Block after Transcatheter
Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2016,(9):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
[2]谢晓川,饶莉.经导管主动脉瓣植入术临床研究进展[J].心血管病学进展,2015,(6):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
XIE Xiaochuan,RAO Li.Clinical Research Progress in Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(9):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
[3]刘新民 宋光远 吴永健.左心室导丝起搏技术在经导管主动脉瓣置换术中的应用[J].心血管病学进展,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
LIU Xinmin,SONG Guangyuan,WU Yongjian.Application of Left Ventricular Guidewire Pacing in Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(9):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
[4]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[5]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(9):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
[6]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(9):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[7]张木馨 李丽英 阮海燕 何森.经导管主动脉瓣置换术后抗栓治疗进展[J].心血管病学进展,2022,(6):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
ZHANG Muxin,LI Liying,RUAN Haiyan,et al.Progress of Antithrombotic Therapy after?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(9):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
[8]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(9):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[9]胡正 陈祥 洲陈静.经导管主动脉瓣置换术后冠状动脉阻塞的研究进展[J].心血管病学进展,2023,(5):402.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.005]
HUZheng,CHENXiangzhou,CHENJing.Coronary Occlusion of Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2023,(9):402.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.005]
[10]刘雅靓 张静 苟中山 黄青霞 杨娅.二叶主动脉瓣的分型与临床意义[J].心血管病学进展,2024,(6):484.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.002]
LIU Yaliang,ZHANG Jing,GOU Zhongshan,et al.Classification and Clinical Significance of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2024,(9):484.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.002]
[11]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(9):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[12]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[13]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(9):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[14]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(9):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[15]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[16]达尼亚尔·迪力木拉提 施林 严飞.二叶式主动脉瓣发病机制及其临床诊治的研究进展[J].心血管病学进展,2023,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
Daniyar·Dilmurat,SHI Lin,YAN Fei.The PathogenesisClinical Diagnosis and Treatment of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2023,(9):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
[17]吴文军 谢玲 李婷婷 丁任重 胡义杰.经导管主动脉瓣置换术围手术期脑卒中和脑保护研究进展[J].心血管病学进展,2024,(4):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
WU Wenjun,XIE Ling,LI Tingting,et al.Perioperative Transcatheter Aortic Valve Replacement for Stroke and Cerebral Protection[J].Advances in Cardiovascular Diseases,2024,(9):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
[18]吴奕璇 邓少东 陈建英.经导管主动脉瓣置换术后瓣周漏相关危险因素研究进展[J].心血管病学进展,2024,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.001]
WU Yixuan,DENG Shaodong,CHEN Jianying.Risk Factors Related to Perivalvular Leakage After Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2024,(9):481.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.001]
[19]陈道乾 何胜虎.重度主动脉瓣狭窄合并慢性肾脏病患者经导管主动脉瓣置换术研究进展[J].心血管病学进展,2024,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.004]
CHEN Daoqian,HE Shenghu.Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis Combined with Chronic Kidney Disease:a Study in Progress[J].Advances in Cardiovascular Diseases,2024,(9):686.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.004]
[20]杨振宇 方伟 任何 胡健强 马文帅 王秋和 李妍.经导管主动脉瓣置换术后生物瓣功能障碍的研究进展[J].心血管病学进展,2024,(8):690.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.005]
YANG Zhenyu,FANG Wei,REN He,et al.Research Progress of Bioprosthetic Valve Dysfunction After?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2024,(9):690.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.005]